$0.00
Shopping Cart
Facebook-f Instagram
Search
Close this search box.
Donate

Clinical Trial Record

Return to Clinical Trials

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

2024-06-17

2025-03-31

2025-03-31

24000

Study Overview

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.

N/A

  • Pancreatic Cancer
  • DRUG: Exenatide
  • DRUG: Non-GLP-1 RA based glucose lowering drugs
  • D5551R00015

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-10-11  

N/A  

2024-06-11  

2022-12-21  

N/A  

2024-06-12  

2022-12-23  

N/A  

2024-06  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Initiators of exenatide

Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide during the study period, 2006 to 2023

DRUG: Exenatide

  • All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
: Initiators of non-GLP-1 RA based glucose lowering drugs

Patients with T2DM, aged 18 years or older, who initiated treatment with non-GLP-1 RA based glucose lowering drugs during the study period, 2006 to 2023

DRUG: Non-GLP-1 RA based glucose lowering drugs

  • Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed populationTo estimate the incidence rate (IR) for pancreatic cancer associated with exposure to exenatide, compared with exposure to non-GLP-1 RA based GLDs, among patients with T2DM.Follow-up starts from the index date to the study completion, an average of 1.5 years or less
Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed populationTo estimate the hazard ratio (HR) for pancreatic cancer associated with exposure to exenatide, compared with exposure to non-GLP-1 RA based GLDs, among patients with T2DM.Follow-up starts from thr index date to the study completion, an average of 1.5 years or less
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: AstraZeneca Clinical Study Information Center

Phone Number: 1-877-240-9479

Email: [email protected]

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    For inclusion in either exposure group, all of the following inclusion criteria must be fulfilled:
    1. Aged 18 years or older at the index date 2. Individual level data on prescriptions, diagnoses and medical history is available for a minimum of 12 months prior to the index date 3. A diagnosis of T2DM on index date or prior to index date
    For inclusion in the overall exenatide exposure group, the following criterion must be fulfilled:
    1. One incident prescription (or incident dispensed prescription) for exenatide (BYETTA or BYDUREON/ BYDUREON BCise) between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
    For inclusion in the BYDUREON/ BYDUREON BCise exposure group, for the analyses of the secondary objective, the criterion a) is substituted with criterion b): 2. One incident prescription (or incident dispensed prescription) for BYDUREON/ BYDUREON BCise between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
    For inclusion in the comparator group, the following criterion must be fulfilled: 3. One incident prescription (or incident dispensed prescription) of a GLD between the start and 12 months before the end of the study period. The GLD must not be a DPP-4i, a GLP-1 RA, or a combination with either a DPP-4i or a GLP-1 RA. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period.
    Patients are not eligible for any of the study population groups if they fulfil any of the following exclusion criteria:
    1. A diagnosis of type 1 diabetes mellitus (T1DM) on index date or a diagnosis of T1DM during the baseline period that is not succeeded by a T2DM diagnosis during the remaining part of the baseline period. 2. A diagnosis of gestational diabetes during the baseline period or on index date. 3. A diagnosis of polycystic ovarian syndrome during the baseline period or on index date in combination with exposure to metformin (Anatomical Therapeutic Chemical Classification System (ATC) code of the World Health Organization (WHO): A10BA02) as the only GLD on index date or during the baseline period. 4. History of any cancer on or prior to index date. The only exception is that nonmelanoma skin cancer does not lead to exclusion. 5. History of any acute pancreatitis, other diseases of the pancreas, or disorders of the pancreas on or prior to index date. 6. One or more prescriptions (or dispensed prescriptions) of a GLP-1 RA (incretin mimetics) other than exenatide on or prior to index date. 7. One or more prescriptions (or dispensed prescriptions) of DPP-4i (incretin mimetics) on or prior to the index date.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Fabian Hoti, PhD, Iqvia Pty Ltd

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved

    Donate Now Online
    Other Ways to Donate